However, such antibodies have been found to be ineffective against medulloblastomas, partly due to the fact that HER2 surface expression in medulloblastoma is lower than in breast cancer and not associated with HER2 gene amplification [11]. This evidence concerns the gene ERBB2 and medulloblastoma.